Voranigo
Voranigo ingredients
| Active ingredient | Strength |
|---|---|
| Vorasidenib | 40 mg/1, 10 mg/1 |
What Voranigo is used for
The FDA lists the approved uses on the official label (below). In the EU, vorasidenib is approved as Voranigo for:
Voranigo as monotherapy is indicated for the treatment of predominantly non‑enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy (see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Voranigo
- Generic name
- Vorasidenib
- Made by
- Servier Pharmaceuticals LLC
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Isocitrate Dehydrogenase 1 Inhibitor, Isocitrate Dehydrogenase 2 Inhibitor
- FDA approval
- New drug application (NDA) NDA218784
- On the US market since
- 2024
Official information
- MedlinePlus drug information (search for Vorasidenib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Voranigo?
Voranigo (Vorasidenib) is a cancer medicine made by Servier Pharmaceuticals LLC, approved by the US FDA.
What are the ingredients of Voranigo?
Voranigo contains Vorasidenib (40 mg/1, 10 mg/1).
Is Voranigo approved in Europe?
The same active substance is approved in the EU as Voranigo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA